文献速递胃肠外科肝胆胰外科围术期管理与 ERAS

新辅助治疗后II型胃食管结合部肿瘤手术入路的多国中心回顾性队列分析

Impact of the Surgical Approach for Neoadjuvantly Treated Gastroesophageal Junction Type II Tumors: A Multinational, High-volume Center Retrospective Cohort Analysis.
PubMed 文献 · Ann Surg · 2023-07-31

该多国高容量中心回顾性队列纳入2012至2021年800例接受新辅助放化疗或围手术期化疗的II型胃食管结合部腺癌患者,比较经膈肌胃切除术(THG)与经胸食管切除术(TTE)的肿瘤学结局。TTE组中位总生存期更长(78.0 vs 40.0个月,P=0.013),倾向性评分匹配后仍保持生存获益(P=0.04),TTE为较长生存的独立预测因素。

要点

  • TTE组中位总生存期78.0个月,THG组40.0个月,差异有统计学意义(P=0.013)。
  • 倾向性评分匹配后TTE组R0切除率更高(P=0.004),生存获益持续(P=0.04)。
  • 无远处转移亚组(P=0.037)及仅接受新辅助化疗亚组(P=0.021)均证实TTE生存优势。

核心结论

  • 在高容量中心,TTE因肿瘤学结局更优应被视为II型胃食管结合部肿瘤的首选手术入路,但仍需等待随机CARDIA试验结果。

研究设计与样本

  • 多国高容量中心回顾性队列分析,基于5个前瞻性维护数据库,纳入2012至2021年800例接受新辅助放化疗或围手术期化疗的II型胃食管结合部腺癌患者。
  • 主要终点为中位总生存期(mOS),采用倾向性评分匹配以减少选择偏倚。

主要发现

  • THG组(n=163,20.4%)ASA分级和cT分期高于TTE组(n=637,79.6%)(P<0.001),且THG组主要接受化疗(87.1%,P<0.001)。
  • TTE组肿瘤退缩更明显(P=0.009),ypT/ypM分期更低(均P<0.001),淋巴结获取数更高(P=0.009),R0切除率更高(P=0.001)。
  • TTE组中位总生存期更长(78.0 vs 40.0个月,P=0.013)。
  • 倾向性评分匹配后,TTE组R0切除率更高(P=0.004),mOS获益持续(P=0.04)。
  • 亚组分析显示无远处转移患者(P=0.037)和仅接受新辅助化疗患者(P=0.021)中TTE的生存获益得到确认,TTE为较长生存的独立预测因素。

临床怎么用

  • 在高容量中心,对接受新辅助治疗的II型胃食管结合部腺癌患者,可优先考虑经胸食管切除术(TTE)以改善肿瘤学结局。
  • 手术决策仍需结合患者个体情况、麻醉风险评估及中心经验综合判断。

局限性

  • 本研究为回顾性队列分析,尽管采用倾向性评分匹配,仍可能存在选择偏倚和未测量混杂因素。
  • THG组与TTE组在新辅助治疗类型(THG组主要接受化疗)及基线分期上存在差异。
  • 最终结论需等待随机CARDIA试验结果证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to explore oncologic outcomes of transhiatal gastrectomy (THG) or transthoracic esophagectomy (TTE) for neoadjuvantly treated gastroesophageal junction (GEJ) Siewert type II adenocarcinomas, a multinational, high-volume center cohort analysis was undertaken. BACKGROUND: Neoadjuvant radiochemotherapy or perioperative chemotherapy (CTx) followed by surgery is the standard therapy for locally advanced GEJ. However, the optimal surgical approach for type II GEJ tumors remains unclear, as the decision is mainly based on individual experience and assessment of operative risk. METHODS: A retrospective analysis of 5 prospectively maintained databases was conducted. Between 2012 and 2021, 800 patients fulfilled inclusion criteria for type II GEJ tumors and neoadjuvant radiochemotherapy or CTx. The primary endpoint was median overall survival (mOS). Propensity score matching was performed to minimize selection bias. RESULTS: Patients undergoing THG (n=163, 20.4%) had higher American Society of Anesthesiologists (ASA) classification and cT stage ( P <0.001) than patients undergoing TTE (n=637, 79.6%). Neoadjuvant therapy was different as the THG group were mainly undergoing CTx (87.1%, P <0.001). The TTE group showed higher tumor regression ( P =0.009), lower ypT/ypM categories (both P <0.001), higher nodal yield ( P =0.009) and higher R0 resection rate ( P =0.001). The mOS after TTE was longer (78.0 vs 40.0 months, P =0.013). After propensity score matching a higher R0 resection rate ( P =0.004) and mOS benefit after TTE remained ( P =0.04). Subgroup analyses of patients without distant metastasis ( P =0.037) and patients only after neoadjuvant chemotherapy ( P =0.021) confirmed the survival benefit of TTE. TTE was an independent predictor of longer survival. CONCLUSION: Awaiting results of the randomized CARDIA trial, TTE should in high-volume centers be considered the preferred approach due to favorable oncologic outcomes.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Wirsik NM, Schmidt T, Nienhüser H, et al. Impact of the Surgical Approach for Neoadjuvantly Treated Gastroesophageal Junction Type II Tumors: A Multinational, High-volume Center Retrospective Cohort Analysis. Ann Surg. 2023. PMID: 37522845. doi:10.1097/SLA.0000000000006011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。